Esperion Therapeutics, Inc.
ESPR
$1.50
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 185.66% | 187.12% | 215.98% | 183.74% | 54.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 185.66% | 187.12% | 215.98% | 183.74% | 54.14% |
| Cost of Revenue | -11.23% | -21.80% | -25.39% | -30.27% | -11.32% |
| Gross Profit | 1,767.75% | 645.46% | 398.67% | 256.73% | 81.48% |
| SG&A Expenses | 14.42% | 41.52% | 45.93% | 42.36% | 30.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.21% | 7.88% | 5.87% | -0.62% | 6.64% |
| Operating Income | 134.97% | 110.57% | 102.91% | 81.26% | 13.34% |
| Income Before Tax | 75.27% | 58.36% | 55.68% | 63.75% | 10.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.27% | 58.36% | 55.68% | 63.75% | 10.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.27% | 58.36% | 55.68% | 63.75% | 10.45% |
| EBIT | 134.97% | 110.57% | 102.91% | 81.26% | 13.34% |
| EBITDA | 135.07% | 110.63% | 102.97% | 81.28% | 13.19% |
| EPS Basic | 89.21% | 73.80% | 70.22% | 71.60% | 40.41% |
| Normalized Basic EPS | 102.95% | 85.75% | 80.27% | 71.64% | 40.22% |
| EPS Diluted | 88.06% | 72.79% | 69.37% | 70.90% | 40.32% |
| Normalized Diluted EPS | 101.12% | 84.12% | 78.89% | 70.50% | 40.22% |
| Average Basic Shares Outstanding | 81.71% | 78.37% | 77.01% | 77.68% | 55.18% |
| Average Diluted Shares Outstanding | 86.65% | 83.83% | 83.21% | 84.89% | 55.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
